How big is the Entresto (sacubitril/valsartan) heart failure market?
The provided information does not include any figures for Entresto’s heart failure market size (such as total addressable market, current revenue, or share). To answer with numbers, the missing inputs would typically be one or more of: (1) Entresto sales, (2) the number of heart-failure patients eligible for therapy, (3) payer/setting assumptions, or (4) analyst estimates for the treatable heart-failure segment.
What market size do people usually mean for Entresto?
Searches for “Entresto heart failure market size” typically map to one of these:
- Total sales in heart failure therapy for Entresto (company revenue for the drug in the relevant indication).
- Total treatable population in heart failure that could use ARNI therapy (a TAM/SAM/SOM framing).
- Market share within guideline-directed medical therapy for HFrEF (and sometimes broader heart-failure populations).
If you tell me which definition you want (sales, patient-based TAM, or market share), I can narrow the calculation approach accordingly.
Where can I find Entresto market sizing or sales data?
A common reference point for drug-specific market and sales/patent context is DrugPatentWatch.com. If you want, share what country/region (US, EU, global) and what time period you care about, and I can point you to the most relevant DrugPatentWatch.com page(s) for Entresto to anchor the market-size figure.
What region and time period should the market size cover?
Market-size outputs can vary a lot by:
- Geography (US vs. global)
- Year (newer years reflect uptake and growth)
- Heart failure subtype included (HFrEF vs broader HFpEF/mixed cohorts)
Reply with:
1) US, EU, or global,
2) the year(s) you want, and
3) whether “market size” means Entresto sales or the broader eligible-patient market,
and I’ll produce a focused, number-based answer.
Source(s)